Knowledge and practice in the management of asymptomatic hyperuricemia among primary health care physicians in Jeddah, Western Region of Saudi Arabia

References

1. ↵
   1. Bardin T

   (2015) Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine 82:141–143.

   OpenUrlCrossRefPubMed
2. ↵
   1. Bardin T,
   2. Richette P

   (2014) Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 26:186–191.

   OpenUrlCrossRefPubMed
3. ↵
   1. Rho YH,
   2. Zhu Y,
   3. Choi HK

   (2011) The epidemiology of uric acid and fructose. Semin Nephrol 31:410–419.

   OpenUrlCrossRefPubMed
4. ↵
   1. Kedar E,
   2. Simkin PA

   (2012) A perspective on diet and gout. Adv Chronic Kidney Dis 19:392–397.

   OpenUrlPubMed
5. ↵
   1. Chuang SY,
   2. Lee SC,
   3. Hsieh YT,
   4. Pan WH

   (2011) Trends in hyperuricemia and gout prevalence:Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. Asia Pac J Clin Nutr 20:301–308.

   OpenUrlPubMed
6. ↵
   1. Mustafa H

   (2014) To treat or not to treat asymptomatic hyperuricemia. Saudi J Med Med Sci 2:95–100.

   OpenUrl
7. ↵
   1. Mandell BF

   (2008) Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med 75:S5–S8.

   OpenUrlAbstract/FREE Full Text
8. ↵
   1. Choi HK,
   2. Curhan G

   (2007) Independent impact of gout on mortality and risk for coronary heart disease. Circulation 116:894–900.

   OpenUrlAbstract/FREE Full Text
9. 1. Kim SY,
   2. Guevara JP,
   3. Kim KM,
   4. Choi HK,
   5. Heitjan DF,
   6. Albert DA

   (2010) Hyperuricemia and coronary heart disease:a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 62:170–180.

   OpenUrl
10. 1. Choi HK,
    2. Ford ES

    (2007) Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 120:442–447.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Choi HK,
    2. Ford ES

    (2008) Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey. Rheumatology (Oxford) 47:713–717.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Khanna D,
    2. Fitzgerald JD,
    3. Khanna PP,
    4. Bae S,
    5. Singh MK,
    6. Neogi T,
    7. et al.

    (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 1:systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64:1431–1446.

    OpenUrl
13. ↵
    1. Khanna D,
    2. Khanna PP,
    3. Fitzgerald JD,
    4. Singh MK,
    5. Bae S,
    6. Neogi T,
    7. et al.

    (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 2:therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64:1447–1461.

    OpenUrl
14. ↵
    1. Desideri G,
    2. Puig JG,
    3. Richette P

    (2015) The management of hyperuricemia with urate deposition. Curr Med Res Opin 31:27–32.

    OpenUrl
15. ↵
    1. Campion EW,
    2. Glynn RJ,
    3. DeLabry LO

    (1987) Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 82:421–426.

    OpenUrlCrossRefPubMed
16. ↵
    1. Pineda C,
    2. Amezcua-Guerra LM,
    3. Solano C,
    4. Rodriguez-Henríquez P,
    5. Hernández-Díaz C,
    6. Vargas A,
    7. et al.

    (2011) Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia:an ultrasound controlled study. Arthritis Res Ther 13:R4.

    OpenUrlCrossRefPubMed
17. ↵
    1. Kawashima M,
    2. Wada K,
    3. Ohta H,
    4. Terawaki H,
    5. Aizawa Y

    (2011) Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers:a long-term retrospective cohort study. BMC Nephrol 12:31.

    OpenUrlCrossRefPubMed
18. ↵
    1. Vinik O,
    2. Wechalekar MD,
    3. Falzon L,
    4. Buchbinder R,
    5. van der Heijde DM,
    6. Bombardier C

    (2014) Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events:a systematic literature review. J Rheumatol Suppl 92:70–74.

    OpenUrlAbstract/FREE Full Text
19. ↵
    1. Sircar D,
    2. Chatterjee S,
    3. Waikhom R,
    4. Golay V,
    5. Raychaudhury A,
    6. Chatterjee S,
    7. et al.

    (2015) Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia:A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Am J Kidney Dis 66:945–950.

    OpenUrlCrossRefPubMed
20. ↵
    1. Qaseem A,
    2. Harris RP,
    3. Forciea MA

    (2017) Management of Acute and Recurrent Gout:A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med 166:58–68.

    OpenUrlCrossRefPubMed
21. ↵
    1. Duskin-Bitan H,
    2. Cohen E,
    3. Goldberg E,
    4. Shochat T,
    5. Levi A,
    6. Garty M,
    7. et al.

    (2014) The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort. Clin Rheumatol 33:549–553.

    OpenUrlCrossRefPubMed
22. ↵
    1. Dalbeth N,
    2. Bardin T,
    3. Doherty M,
    4. Lioté F,
    5. Richette P,
    6. Saag KG,
    7. et al.

    (2017) Discordant American College of Physicians and international rheumatology guidelines for gout management:consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat Rev Rheumatol 13:561–568.

    OpenUrlCrossRef
23. ↵
    1. Al-Arfaj AS

    (2001) Hyperuricemia in Saudi Arabia. Rheumatol Int 20:61–64.

    OpenUrlPubMed
24. ↵
    1. Mikuls TR,
    2. Farrar JT,
    3. Bilker WB,
    4. Fernandes S,
    5. Saag KG

    (2005) Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia:results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 44:1038–1042.

    OpenUrlCrossRefPubMedWeb of Science
25. ↵
    1. Bleyer AJ,
    2. Hart TC

    (2006) Genetic factors associated with gout and hyperuricemia. Adv Chronic Kidney Dis 13:124–130.

    OpenUrlCrossRefPubMedWeb of Science
26. ↵
    1. Pillinger MH,
    2. Rosenthal P,
    3. Abeles AM

    (2007) Hyperuricemia and gout:new insights into pathogenesis and treatment. Bull NYU Hosp Jt Dis 65:215–221.

    OpenUrlPubMed
27. ↵
    1. Kuwabara M,
    2. Niwa K,
    3. Hisatome I,
    4. Nakagawa T,
    5. Roncal-Jimenez CA,
    6. Andres-Hernando A,
    7. et al.

    (2017) Asymptomatic Hyperuricemia Without Comorbidities Predicts Cardiometabolic Diseases:Five-Year Japanese Cohort Study. Hypertension 69:1036–1044.

    OpenUrlPubMed